Beermann J L, Thiesler C T, Dringenberg U, Alter C, Kuhs S, Velaga S, Ukena S N, Franzke A
Department of Hematology and Oncology, Hannover Medical School, Carl-Neuberg Str. 1, Hannover, Germany.
Transpl Immunol. 2017 Dec;45:29-34. doi: 10.1016/j.trim.2017.08.005. Epub 2017 Sep 1.
Adoptively transferred regulatory T-cells represent a promising therapeutic approach for tolerance induction in autoimmunity and transplantation medicine. However, a major hurdle for clinical application is the manufacturing of sufficient Treg cell numbers with respect to the low frequency of naturally occurring Tregs in the peripheral blood. Therefore, ex vivo large-scale expansion is mandatory for most of the clinical conditions. Besides the Treg cell number other parameters of the cell product are of high relevance for safe and efficient clinical Treg cell application like Treg cell purity, suppressive capacity and genetic stability of the Treg cell phenotype. Moreover, migratory properties of ex vivo expanded Tregs should be defined very clearly in order to predict their migration to secondary lymphoid organs as sites of antigen-specific activation, in vivo proliferation and subsequent trafficking to affected target organs. Therefore, we studied different cell culture conditions for Treg large-cell expansion using all-trans retinoic acid (ATRA) and/or rapamycin (Rapa) with focus on their migratory properties. The tested culture conditions revealed comparable chemokine receptor expression profiles (CXCR3, CCR4, CCR6, CCR7) and functional migration capabilities (IP10 and CCL19) with respect to Th1 and Th2 inflammatory conditions. However, the most striking difference was detected for the expansion capacity, suppressive potency and genetic stability likely predisposing large-scale expansion with ATRA and/or Rapa for therapeutic intervention in acute GvHD and without supplementation for chronic GvHD.
过继转移调节性T细胞是自身免疫性疾病和移植医学中诱导免疫耐受的一种很有前景的治疗方法。然而,临床应用的一个主要障碍是,由于外周血中天然存在的调节性T细胞频率较低,难以制备足够数量的调节性T细胞。因此,对于大多数临床情况而言,体外大规模扩增是必不可少的。除了调节性T细胞数量外,细胞产品的其他参数对于调节性T细胞临床安全有效应用也具有高度相关性,如调节性T细胞纯度、抑制能力和调节性T细胞表型的遗传稳定性。此外,为了预测体外扩增的调节性T细胞迁移至作为抗原特异性激活位点的次级淋巴器官、体内增殖以及随后向受影响靶器官的转运,应明确界定其迁移特性。因此,我们研究了使用全反式维甲酸(ATRA)和/或雷帕霉素(Rapa)进行调节性T细胞大规模扩增的不同细胞培养条件,重点关注其迁移特性。在所测试的培养条件下,相对于Th1和Th2炎症条件,调节性T细胞表现出相当的趋化因子受体表达谱(CXCR3、CCR4、CCR6、CCR7)和功能性迁移能力(IP10和CCL19)。然而,在扩增能力、抑制效力和遗传稳定性方面检测到了最显著的差异,这可能使得使用ATRA和/或Rapa进行大规模扩增适用于急性移植物抗宿主病的治疗干预,而对于慢性移植物抗宿主病则无需补充。